NNVC - NanoViricides, Inc. | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical NNVC - NanoViricides, Inc.

Previous 10 Next 10

To: jmhollen who wrote (22)	7/19/2005 4:50:16 PM
From: donpat	of 12869

Indeed! My (our) usual method is to get in when there are two or three zeros to the right of the decimal place. In this case it didn't happen! I don't think they gave us that opportunity! We must make hay while the sun shines and it is shining bright on NNVC, IMHO!

Share	RecommendKeepReply Mark as Last Read

From: donpat	7/19/2005 10:27:01 PM
	of 12869

UCLA Chemists Create Nano Valve Date: July 15, 2005 Contact: Stuart Wolpert ( stuartw@college.ucla.edu ) Phone: 310-206-0511 UCLA chemists have created the first nano valve that can be opened and closed at will to trap and release molecules. The discovery, federally funded by the National Science Foundation, will be published July 19 in the Proceedings of the National Academy of Sciences. "This paper demonstrates unequivocally that the machine works," said Jeffrey I. Zink, a UCLA professor of chemistry and biochemistry, a member of the California NanoSystems Institute at UCLA, and a member of the research team. "With the nano valve, we can trap and release molecules on demand. We are able to control molecules at the nano scale. "A nano valve potentially could be used as a drug delivery system," Zink said. "The valve is like a mechanical system that we can control like a water faucet," said UCLA graduate student Thoi Nguyen, lead author on the paper. "Trapping the molecule inside and shutting the valve tightly was a challenge. The first valves we produced leaked slightly." "Thoi was a master nano plumber who plugged the leak with a tight valve," Zink said. This nano valve consists of moving parts — switchable rotaxane molecules that resemble linear motors designed by California NanoSystems Institute director Fraser Stoddart's team — attached to a tiny piece of glass (porous silica), which measures about 500 nanometers, and which Nguyen is currently reducing in size. Tiny pores in the glass are only a few nanometers in size. "It's big enough to let molecules in and out, but small enough so that the switchable rotaxane molecules can block the hole," Zink said. The valve is uniquely designed so one end attaches to the opening of the hole that will be blocked and unblocked, and the other end has the switchable rotaxanes whose movable component blocks the hole in the down position and leaves it open in the up position. The researchers used chemical energy involving a single electron as the power supply to open and shut the valve, and a luminescent molecule that allows them to tell from emitted light whether a molecule is trapped or has been released. Switchable rotaxanes are molecules composed of a dumbbell component with two stations between which a ring component can be made to move back and forth in a linear fashion. Stoddart, who holds UCLA's Fred Kavli Chair in nanosystems sciences, has already shown how these switchable rotaxanes can be used in molecular electronics. Stoddart's team is now adapting them for use in the construction of artificial molecular machinery. "The fact that we can take a bistable molecule that behaves as a switch in a silicon-based electronic device at the nanoscale level and fabricate it differently to work as part of a nano valve on porous silica is something I find really satisfying about this piece of research," Stoddart, said. "It shows that these little pieces of molecular machinery are highly adaptable and resourceful, and means that we can move around in the nanoworld with the same molecular tool kit and adapt it to different needs on demand." In future research, they will test how large a hole they can block, to see whether they can get larger molecules, like enzymes, inside the container; they are optimistic. The research team also includes Hsian-Rong Tseng, a former postdoctoral scholar in chemistry who is now an assistant professor of molecular and medical pharmacology in UCLA's David Geffen School of Medicine; Paul Celestre, a former undergraduate student in Stoddart's laboratory; Amar Flood, a former UCLA researcher in Stoddart's supramolecular chemistry group who is now an assistant professor of chemistry at Indiana University; and Yi Liu, a former UCLA graduate student who is now a postdoctoral scholar at the Scripps Research Institute in La Jolla. "Our team and Fraser's have very different areas of expertise," Zink said. "By combining them and working together we were able to make something new that really works." Stoddart has noted that it is only in the past 100 years that humankind has learned how to fly. Prior to the first demonstration of manned flight, there were many great scientists and engineers who said it was impossible. "Building artificial molecular machines and getting them to operate is where airplanes were a century ago," Stoddart said. "We have come a long way in the last decade, but we have a very, very long way to go yet to realize the full potential of artificial molecular machines." The nano valve is much smaller than living cells. Could a cell ingest a nano valve combined with bio-molecules, and could light energy then be used to release a drug inside a cell? Stay tuned. newsroom.ucla.edu

Share	RecommendKeepReply Mark as Last Read

From: Lateott	7/20/2005 12:02:57 PM
	of 12869

Hey Guys, Not trying to bash or anything of that nature. But are we concerned about the phrase "...has exclusive license in perpetuity for technologies developed by Theracour Pharma..."? Only reason I ask is that I'm still licking my fresh wounds from HTDS. Are we aware of any termination clauses... etc? Any thoughts would be appreciated? Thanks, Lateott

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Lateott who wrote (25)	7/20/2005 2:21:27 PM
From: donpat	of 12869

My thoughts on Theracour Pharma. The US patent issued to "Inventors: Watterson; Arthur C. (Nashua, NH); Danprasert; Kunya (Bangkapi, TH); Diwan; Anil (West Haven, CT)" I think that Theracour Pharma was set up to market that patent: Message 21480742 Diwan is the only inventor now at NNVC. He is also a principle at Theracour Pharma: "Anil and his partners have formed a new company, TheraCour Pharma, Inc., with private investor financing to commercialize these materials and also to develop new drugs based on them." Message 21480615 It looks to me that this approach rewards all inventors for the invention by the royalties received and split however agreed upon, likely equally among the three - the three in Theracour, while the vehicle to commercialize the stuff is NNVC with but one inventor in the picture - Diwan - along with shareholders who will be rewarded as NNVC prospers. It could well have been the case that while Diwan was keen to get involved in the commercialization opportunities the other inventors were not, for whatever reasons - perhaps they preferred to stay wherever they are presently, like in the academic community, perhaps. As I said - this is my take. The company could, and should, perhaps, clarify this question fully. Especially regarding any cancellation provisions of this perpetual licence by Theracour Pharma. As you said, once bitten, twice shy!!!

Share	RecommendKeepReply Mark as Last Read Read Replies (2)

To: donpat who wrote (26)	7/20/2005 3:08:31 PM
From: jmhollen	of 12869

Thanks dp, I really appreciate the input. John :-) .

Share	RecommendKeepReply Mark as Last Read

From: archimedest	7/21/2005 9:09:47 AM
	of 12869

Very interesting article on the NNVC site from NanoBiotech news. It gives you a good idea of their strategy going forward. I expect this stock to continue climbing for a while.

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: archimedest who wrote (28)	7/21/2005 9:29:19 AM
From: donpat	of 12869

NanoViricides' President Discusses New HIV Drugs and Company Goals in Interview with NanoBiotech News Thursday July 21, 8:53 am ET Provides In-Depth Interview of the NanoViricides Story NEW YORK--(BUSINESS WIRE)--July 21, 2005--NanoViricides, Inc. (Pink Sheets:NNVC - News), has announced the online availability of a feature article about NanoViricides, Inc. in the July 13, 2005 edition of NanoBiotech News. In the article, Dr. Diwan discusses NanoViricides' uniqueness and drug development goals as it prepares to compete in the multi-billion-dollar bio-pharmaceutical marketplace. The article can be viewed free of charge by visiting nanoviricides.com [[ARTICLE here: nanoviricides.com ]] Information about NanoBiotech News can be found at nanobiotechnews.com About NanoViricides - nanoviricides.com NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. NanoViricides, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types: HIV, HCV, Herpes, Asian (bird) flu and Influenza. A NanoViricide(TM) is a nanoparticle that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus. When a NanoViricide(TM) drug particle enters the patient's blood stream, it attacks and immobilizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus by the NanoViricide(TM) particle, destroying it. The company plans to develop novel NanoViricide(TM) drugs first against HIV, and anticipates that it will license the products to major pharmaceutical companies. This press release contains forward-looking statements which reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process. -------------------------------------------------------------------------------- Contact: NanoViricides, Inc., New York Leo Ehrlich, 917-853-6440 leo@nanoviricides.com or Anil R. Diwan, Ph.D. adiwan@snet.net -------------------------------------------------------------------------------- Source: NanoViricides, Inc. biz.yahoo.com

Share	RecommendKeepReply Mark as Last Read

To: donpat who wrote (26)	7/21/2005 12:29:48 PM
From: Lateott	of 12869

Thanks donpat, Looking to recoup the flogging I took on HTDS and just trying to to a little DD. Well, let me rephrase, hoping to suck a little DD out of you guys. Your comments, as always, are much appreciated. Thanks again.

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Lateott who wrote (30)	7/21/2005 1:54:24 PM
From: donpat	of 12869

I try! I like this NNVC more than most (other stocks) around here. I think it has some terrific possibilities. And lining our pockets will be an added bonus; I think the contributions this technology could well contribute to mankind is the main benefit. Money is one thing - but some things are more important.

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: donpat who wrote (31)	7/21/2005 4:40:41 PM
From: jmhollen	of 12869

O/T & FYI: If some short term "..recouping.." is desirable, I'd suggest a healthy ACHI collection - ASAP. See Board. John :-) .

Share	RecommendKeepReply Mark as Last Read